Invesco Biotechnology & Genome +$0.59 +0.93% Friday 19:55
1D 1W 1M 3M 1Y 5Y
0.05 % Dividend Yield
This list is based on the watchlists of people on Stock Events who follow PBE. It's not an investment recommendation.
This list is an analysis based on recent market events. It's not an investment recommendation.
iShares Biotechnology
IBB
Mkt Cap 7.41B
iShares Nasdaq Biotechnology ETF, tracks a similar biotech index, making it a direct competitor in the biotech ETF space. SPDR Biotech
XBI
Mkt Cap 7.19B
SPDR S&P Biotech ETF, offers exposure to the biotechnology sector, competing directly with PBE in terms of sector focus. VanEck Biotech
BBH
Mkt Cap 433.07M
VanEck Vectors Biotech ETF, focuses on biotech firms, closely competing with PBE's investment theme. First Trust NYSE Arca Biotechnology Index Fund
FBT
Mkt Cap 1.12B
First Trust NYSE Arca Biotechnology Index Fund, targets the biotech industry, similar to PBE's investment strategy. Principal Healthcare Innovators
BTEC
Mkt Cap 16.4M
Principal Healthcare Innovators Index ETF, invests in healthcare innovation, including biotech, making it a competitor. ARK Genomic Revolution
ARKG
Mkt Cap 1.28B
ARK Genomic Revolution ETF, focuses on genomic revolution, directly competing with PBE's genome investment focus. ALPS Medical Breakthroughs
SBIO
Mkt Cap 104.11M
ALPS Medical Breakthroughs ETF, targets biotech and healthcare breakthroughs, competing in the same niche as PBE. Virtus LifeSci Biotech Clinical Trials
BBC
Mkt Cap 10.22M
Virtus LifeSci Biotech Clinical Trials ETF, focuses on biotech clinical trials, offering a similar investment focus to PBE. Global X Genomics & Biotechnology
GNOM
Mkt Cap 95.21M
Global X Genomics & Biotechnology ETF, specifically targets the genomics sector, making it a direct competitor to PBE's genome focus. iShares Genomics Immunology and Healthcare
IDNA
Mkt Cap 135.25M
iShares Genomics Immunology and Healthcare ETF, focuses on genomics and immunology, competing with PBE's thematic investment approach. Miscellaneous
Investment Trusts/Mutual Funds
The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying intellidex. The underlying intellidex was composed of common stocks of U.S. biotechnology and genome companies. These companies are engaged principally in the research, development, manufacture and marketing and distribution of various biotechnological products, services and processes, etc. It is non-diversified.
Show more...